QBKPN is under clinical development by Qu Biologics and currently in Phase II for Respiratory Tract Infections. According to GlobalData, Phase II drugs for Respiratory Tract Infections have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how QBKPN’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QBKPN overview
QBKPN-SSI is under development for the treatment of non-small cell lung cancer, asthma, respiratory tract infections, coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and chronic obstructive pulmonary disease. It is administered subcutaneously. It consists of components of inactivated Klebsiella pneumoniae. The drug candidate acts as immunomodulator and cell process modulator. The drug candidate is based on site specific immunotherapy (SSIs) technology.
Qu Biologics overview
Qu Biologics is a biotechnology company that discovers and develops immunotherapies for the treatment of cancer and other immune-related diseases. It utilizes its site-specific immunomodulators (SSI), a novel proprietary immunotherapy platform to restore normal immune function in the targeted tissue to reverse chronic inflammation in diseases including cancer, inflammatory bowel disease, and other immune-related conditions. Its therapies are also used to treat lung cancer, gastric, kidney, and prostate cancer, ovarian cancer, bone cancer, ulcerative colitis, and arthritis. Qu Biologics also offers preclinical research, retrospective studies, compassionate use program, and clinical trial programs. The company works in collaboration with pharmaceutical companies and academic institutions to develop its products. Qu Biologics is headquartered in Burnaby, British Columbia, Canada.
For a complete picture of QBKPN’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
